Cerbios is a Swiss CDMO with more than 45 years of experience in the pharmaceutical industry. Cerbios specializes in manufacturing generic APIs and HPAPIs, as well as finished formulations based on its own probiotic strain, and exclusive CDMO services for HPAPIs, ADCs, and recombinant proteins. The company offers process and (DS) analytical development, scale-up and clinical supply, industrial validation, commercial supply, and full CMC support. Cerbios also provides continuous flow chemistry and high-performance liquid chromatography to support their small molecule offering. In 2025, HAS Healthcare Advanced Synthesis acquired Cerbios, forming a HAS Group of CDMOs in a highly complementary arrangement.